In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3- dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase

Drug Metabolism and Disposition

Volumn 36, Issue 5, 2008, Pages 894-903

  Albrecht, Wolfgang ^a,d   Unger, Anke ^a   Nussler, Andreas K ^c,e   Laufer, Stefan ^b  

^a C a i r Biosciences GmbH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d TEVA PHARMACEUTICALS   (Israel)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450; CYTOCHROME P450 2C8; DICLOFENAC; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; HYDROXYGLUCURONIDE; ISOENZYME; LICOFELONE; MONTELUKAST; PACLITAXEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME SPECIFICITY; GLUCURONIDATION; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RAT;

ACETATES; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; LIPOXYGENASE INHIBITORS; MACACA FASCICULARIS; MICE; MICE, INBRED STRAINS; MICROSOMES; PACLITAXEL; PYRROLES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

MACACA FASCICULARIS; RATTUS;

EID: 42449097701     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020347     Document Type: Article

References (33)

1. Alvaro-Gracia JM (2004) Licofelone - clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology 43 (Suppl 1):i21-i25.
2. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117-137.
3. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, and Lasagna L (1995) Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 to 1993: a regulatory perspective. Clin Pharmacol Ther 58:108-117.
4. Bias P, Buchner A, Klesser B, and Laufer S (2004) The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 99:611-618.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Clària J and López-Parra M (2005) New perspectives in the modulation of the eicosanoid cascade in inflammation. Lett Drug Des Discov 2:391-402.
7. Dai D, Zeldin DC, Blaisdell J Chanas B, Coulter SJ, Ghanayem BI, and Goldstein JA (2001) Polymorphism in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607.
8. Delaforge M, Pruvost A, Perrin L, and André F (2005) Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17β-glucuronide oxidation to 2-hydroxy-estradiol-17β- glucuronide by CP 2C8. Drug Metab Dispos 33:466-473.
9. Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
10. Grillo MP, Knutson CG, Sanders PE, Waldon DJ, Hua F, and Ware JA (2003) Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab Dispos 31:1327-1336.
11. Grosser T, Fries S, and FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4-15.
12. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, and Funae Y (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298-304.
13. Kirschning M, Ries S, Domann W, Martin Albrecht W, Arnold P, and Laufer S (1997) Synthesis and biological identification of the acylglucuronide of the anti-inflammatory drug ML 3000. Bioorg Med Chem Lett 7:903-906.
14. Kuehl GE, Lampe JW, Potter JD, and Bigler J (2005) Glucuronidation of nonsteroidal anti-inflammatory drugs: Identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 33:1027-1035.
15. Kulkarni SK and Singh VP (2007) Licofelone - a novel analgesic and anti-inflammatory agent. Curr Top Med Chem 7:251-263.
16. Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Lee-Chiu S-H, Evans DC, and Baillie TA (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 303:969-978.
17. Laufer SA, Augustin J, Dannhardt G, and Kiefer W (1994) (6,7-Diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potential dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem 37:1894-1897.
18. Matsumoto S, Hirama T, Matsubara T, Nagata K, and Yamazoe Y (2002) Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30:1240-1245.
19. Moreau M, Daminet S, Martel-Pelletier J, Fernandes J, and Pelletier JP (2005) Superiority of the gastroduoenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J Vet Pharmacol Ther 28:81-86.
20. Moreau M, Lussier B, Doucet M, Vincent G, Martel-Pelletier J, and Pelletier JP (2007) Efficacy of licofelone in dogs with clinical osteoarthritis. Vet Rec 160:584-588.
21. Ogilvie BW, Zhang D, Li W, Rodrigues D, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrotil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
22. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, et al. (1996) Effects of freezing, thawing and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331:145-169.
23. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, and King Ch (2004) Glucuronidation of carboxylic acid containing compounds by UDP- glucuronosyltransferase isoforms. Arch Biochem Biophys 424:219-225.
24. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
25. Skelly MM and Hawkey CJ (2003) COX-LOX inhibition: current evidence for an emerging new therapy. Int J Clin Pract 57:301-304.
26. Spahn-Langguth H, Dahms M, and Hermening A (1996) Acyl glucuronides: covalent binding and its potential relevance. Adv Exp Med Biol 387:313-328.
27. Stachulski AV (2007) The chemistry and biological activity of acyl glucuronides. Curr Opin Drug Dis Dev 10:58-66.
28. Totah RA and Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341-352.
29. Tries S, Neupert W, and Laufer S (2002) The mechanism of action of the new anti-inflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 51:135-143.
30. Walsky RL, Gaman EA, and Obach RS (2005b) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68-78.
31. Walsky RL, Obach RS, Gaman EA, Gleeson JPR, and Proctor WR (2005a) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-418.
32. Wilson ZE, Rostami-Hodjegan A, Burn JL, Tooley A, Boyle J, Ellis SW, and Tucker GT (2003) Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 56:433-440.
33. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, and Brouwer KLR (2006) Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27:447-486.